Clinical Trial Update: Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen [Phase 3]

View source ↗

Summary

A Phase 3 trial assessed switching virologically suppressed HIV-1 patients from a first protease inhibitor–based regimen to an efavirenz-based regimen after ach…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• EFAVIRENZ (efavirenz)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: HIV Infections | Phase 3 | Status: COMPLETED